Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04120480 · ClinicalTrials.gov registry record · NA
Effectiveness of PGx Testing
A NA study of Polypharmacy, sponsored by Kaiser Permanente.
- Active
- Registry status
- NA
- Development phase
- 600
- Enrollment target
- 1
- Study location
NCT04120480: Active NA study of Polypharmacy, sponsored by Kaiser Permanente.
NCT04120480 is a NA study of Polypharmacy that is active but no longer recruiting, run by Kaiser Permanente. The registered enrollment target is 600 participants, below the 1,476-participant average among 11 other Polypharmacy trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04120480, a NA study of Polypharmacy, is active but no longer recruiting, sponsored by Kaiser Permanente.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system. Investigators hypothesize that patients who receive the RightMed® PGx test from OneOme, LLC with subsequent counseling of their prescribers by a study pharmacist, as needed, on the appropriateness of their prescribed medications will experience lower one-year follow-up healthcare utilization and expenditures compared to control patients who receive usual care.
Primary Outcome
Changes in mean/median total healthcare expenditures from the KPCO perspective
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Pharmacogenomic test
Study Locations (1)
Colorado
- Central Support Services - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What the registry record for NCT04120480 still lists
NCT04120480 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,476-participant average among 11 other Polypharmacy trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Polypharmacy appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic test is the first listed.
NCT04120480 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04120480 about?
NCT04120480 is a clinical study titled "Effectiveness of PGx Testing". The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system. Investigators hypothesize that patients who receive the RightMed® PGx...
What is the current status of trial NCT04120480?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2019-11-15. Estimated completion is 2027-12-31.
What conditions does trial NCT04120480 study?
This clinical trial studies the following conditions: Polypharmacy.
What interventions are being tested in trial NCT04120480?
The interventions under investigation include: Pharmacogenomic test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04120480?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04120480 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polypharmacy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04120480's enrollment target sits among peer trials
600 7th of 11 higher than 5 of 11 other Polypharmacy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Polypharmacy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Medication Management in World Trade Center Responders
RECRUITING · NA
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial
ACTIVE NOT RECRUITING · NA
-
Preemptive Pharmacogenomics Testing Among Geriatric Patients
ACTIVE NOT RECRUITING · NA
-
Pharmacist Intervention to Reduce Post-Hospitalization Utilization
ACTIVE NOT RECRUITING · NA
-
A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI